Cabometyx Uni Eropa - Norwegia - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Tibolon Aristo 2.5 mg Norwegia - Norwegia - Statens legemiddelverk

tibolon aristo 2.5 mg

aristo pharma gmbh - tibolon - tablett - 2.5 mg

Ravicti Uni Eropa - Norwegia - EMA (European Medicines Agency)

ravicti

immedica pharma ab - glycerolfenylbutyrat - ureasyklusforstyrrelser, innfødte - andre alimentary tract and metabolism products, - ravicti er indikert for bruk som adjunctive therapy for kronisk behandling av pasienter med urea-syklus lidelser (ucds) inkludert svekkelse av carbamoyl fosfat-syntase-jeg (cps), ornithine carbamoyltransferase (otc), argininosuccinate synthetase (ass), argininosuccinate lyase (asl), arginase jeg (arg) og ornithine translocase mangel hyperornithinaemia-hyperammonaemia homocitrullinuria syndrom (hhh) som ikke er administrert av kosttilskudd protein begrensning og/eller aminosyre kosttilskudd alene. ravicti må brukes med kosttilskudd protein begrensning og, i noen tilfeller, kosttilskudd (e. , essensielle aminosyrer, arginin, citrullin, proteinfri kalori kosttilskudd).

Ovesterin 0.1 % Norwegia - Norwegia - Statens legemiddelverk

ovesterin 0.1 %

aspen pharma trading limited - Østriol - vaginalkrem - 0.1 %

Ovesterin 0.5 mg Norwegia - Norwegia - Statens legemiddelverk

ovesterin 0.5 mg

aspen pharma trading limited - Østriol - vagitorie - 0.5 mg

Cinacalcet Aristo 30 mg Norwegia - Norwegia - Statens legemiddelverk

cinacalcet aristo 30 mg

aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 30 mg

Cinacalcet Aristo 60 mg Norwegia - Norwegia - Statens legemiddelverk

cinacalcet aristo 60 mg

aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 60 mg

Cinacalcet Aristo 90 mg Norwegia - Norwegia - Statens legemiddelverk

cinacalcet aristo 90 mg

aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 90 mg

Zeposia Uni Eropa - Norwegia - EMA (European Medicines Agency)

zeposia

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressive - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Reblozyl Uni Eropa - Norwegia - EMA (European Medicines Agency)

reblozyl

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - andre antianemic preparations - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.